IMR Press / EJGO / Volume 40 / Issue 3 / DOI: 10.12892/ejgo4732.2019
Open Access Case Report
Sertoli-Leydig cell tumor characterized by hyperestrogenism in a postmenopausal woman: a case report and review of the literature
L. Wang1,2,3,4A. Yao1A. Zhang1P. Qu5,*
Show Less
1 The Third Central Clinical College of Tianjin Medical University, Tianjin, China
2 Tianjin Key Laboratory of Artificial Cell, Tianjin, China
3 Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin, China
4 Tianjin Institute of Hepatobiliary Disease, Tianjin; 5Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China
Eur. J. Gynaecol. Oncol. 2019 , 40(3), 502–505;
Published: 10 June 2019

Sertoli-Leydig cell tumor (SLCT) is a rare neoplasm from the group of sex-stromal tumors of ovary, which accounts for < 0.5% of all primary ovarian tumors. The tumor can occur in all ages but is more often seen in young women at the mean age of 25 years. Less than 10% of the SLCTs occur before menarche or after menopause. Although most SLCTs have a good prognosis if detected in Stage I, but the most common are those with moderate or poor differentiation. In order to monitor the risk of disease recurrence, close follow-up is required. In this article the rare case of SLCT in a 62-year-old woman characterized by postmenopausal bleeding and hyperestrogenism was reported. The clinical and pathological characteristics were described. Clinicians should consider that patients with postmenopausal bleeding and hyperestrogenism should be highly suspicious of SLCT, and more prospective studies on the diagnosis and the course of the diseases are needed.

Sertoli-Leydig cell tumor
Postmenopausal bleeding
Figure 1.
Back to top